Prescribing Atomoxetine for Poor CYP2D6 Metabolizers

Understanding CYP2D6 Metabolism and Atomoxetine

• Approximately 5-8% of the Caucasian population are poor metabolizers (PMs) of CYP2D6, a genetically polymorphic enzyme responsible for the primary metabolism of atomoxetine 1

Clinical Considerations for Poor Metabolizers

• Failing to identify CYP2D6 metabolizer status before initiating therapy can lead to excessive drug exposure and adverse effects in poor metabolizers, according to the American Academy of Clinical Pharmacology 2